Target: Acetylated Lysine
Conjugate: ATTO 594
Product Type: Polyclonal
Immunogen: Acetylated KLH Conjugated
Purification: Protein A Purified
Storage Buffer: PBS, 50% glycerol, 0.09% sodium azide *Storage buffer may change when conjugated
Concentration: 1 mg/ml
Specificity: Detects proteins containing acetylated lysine residues. No reaction to non-acetylated proteins.
Scientific Background: Post-translational modifications of proteins play critical roles in the regulation and function of many known biological processes. Proteins can be post-translationally modified in many different ways, and a common post-transcriptional modification of Lysine involves acetylation (1). The conserved amino-terminal domains of the four core histones (H2A, H2B, H3 and H4) contain lysines that are acetylated by histone acetyltransferases (HATs) and deacetylated by histone deacetylases (HDACs) (2). Protein posttranslational reversible lysine Nε-acetylation and deacetylation have been recognized as an emerging intracellular signaling mechanism that plays critical roles in regulating gene transcription, cell-cycle progression, apoptosis, DNA repair, and cytoskeletal organization (3). The regulation of protein acetylation status is impaired in the pathologies of cancer and polyglutamine diseases (4), and HDACs have become promising targets for anti-cancer drugs currently in development (5).
References: 1. Yang X.J. (2005) Oncogene. 24:1653-1662.2. Hassig C.A. and Schreiber S.L. (1997) Curr. Opin. Chem. Biol. 1(3): 300-308.3. Yang X.J. (2004) Bioessays 26:1076-1087.4. Hughes R.E. (2002) Curr. Biol. 12: R141-R143. 5. Vigushin D.M. and Coombes R.C. (2004) Curr. Cancer Drug Targets 4: 205-218.6. Chan H.M. et al. (2001) Nat. Cell Biol. 3: 667-674.7. Martinez-Balbas M.A. et al. (2000) EMBO J. 19: 662-671.
Field of Use: Not for use in humans. Not for use in diagnostics or therapeutics. For in vitro research use only.
English
Deutsch
